News & Updates
Showing Oncology articles
Showing
RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer
Real-world (RW) data presented at ASCO GU 2026 support the use of enfortumab vedotin plus pembrolizumab (EV+P) as frontline treatment for advanced urothelial carcinoma (UC).
RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer
12 Mar 2026
Belzutifan-lenvatinib bests cabozantinib for RCC
A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.
Belzutifan-lenvatinib bests cabozantinib for RCC
11 Mar 2026
PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC
Addition of palbociclib to maintenance therapy yielded a median progression-free survival (mPFS) approaching 4 years, representing an effective first-line (1L) treatment for patients with hormone receptor–positive (HR+), HER2-positive (HER2+) metastatic breast cancer (mBC), according to the phase III PATINA trial.
PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC
11 Mar 2026
Stool-based microbial test transforms colon cancer detection
A stool-based microbial diagnostic test outperforms faecal immunochemical test (FIT) in detecting colorectal cancer (CRC) or advanced adenoma (polyps) in a study conducted in Hong Kong, Singapore and Japan.